Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Panacea BiotecBOM:531349 +4.22%59 PB Ratio is 3.03 as of Aug. 17, 2026, which is 25% above its 10-year median of 2.43. GuruFocus rates BOM:531349 with a GF Score™ of 59/100 and a GF Value™ of ₹363.69 (Modestly Overvalued). Among 1,219 Biotechnology companies, Panacea Biotec ranks worse than 50.62% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-17), Panacea Biotec's share price is ₹413.35. Panacea Biotec's Book Value per Share for the quarter that ended in Mar. 2026 was ₹136.30. Hence, Panacea Biotec's PB Ratio of today is 3.03.
The historical rank and industry rank for Panacea Biotec's PB Ratio or its related term are showing as below:
BOM:531349'
s PB Ratio Range Over the Past 10 Years
Min: 0.79 Med: 2.43 Max: 6.03
Current: 3.03
During the past 13 years, Panacea Biotec's highest PB Ratio was 6.03. The lowest was 0.79. And the median was 2.43.
BOM:531349's PB Ratio is ranked worse than 50.62% of 1219
companies
in the Biotechnology industry
Industry Median: 2.88
vs BOM:531349: 3.03
During the past 3 years, the average Book Value Per Share Growth Rate was -0.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Panacea Biotec was 61.90% per year. The lowest was -18.60% per year. And the median was -1.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Panacea Biotec PB Ratio Related Terms
Panacea Biotec PB Ratio Historical Data
* Premium members only.
The historical data trend for Panacea Biotec's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531349 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Panacea Biotec's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Biotec PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Panacea Biotec's PB Ratio distribution charts can be found below:
* The bar in red indicates where Panacea Biotec's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Panacea Biotec's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Panacea Biotec (BOM:531349) has a PB Ratio of 3.03 as of Aug. 17, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Panacea Biotec and its competitors. This is 25% above median its historical median of 2.43. Over the past decade, Panacea Biotec's PB Ratio has ranged from 0.79 to 6.03. According to the industry distribution chart, Panacea Biotec ranks #617 out of 1219 companies in the Biotechnology industry, placing it in the top 50.6%.
Is Panacea Biotec's PB Ratio too high?
Panacea Biotec's current PB Ratio of 3.03 is 25% above median its 10-year median of 2.43. Over the past 10 years, this metric has ranged from a low of 0.79 to a high of 6.03. The Biotechnology industry median PB Ratio is 2.88. Panacea Biotec's value of 3.03 is 5.2% above this industry median. Based on the distribution chart, Panacea Biotec ranks #617 out of 1219 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Panacea Biotec has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Panacea Biotec's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Panacea Biotec ranks #617 out of 1219 companies for PB Ratio. This places Panacea Biotec in the lower half of its industry. The industry median PB Ratio is 2.88. Panacea Biotec's value of 3.03 is 5.2% above this benchmark. Historically, Panacea Biotec's own PB Ratio has ranged from 0.79 to 6.03 over the past decade. While the company's 10-year median is 2.43 vs. the industry median of 2.88, Panacea Biotec has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.88, based on 1,219 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panacea Biotec's current PB Ratio of 3.03 is 5.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Panacea Biotec and its competitors. For the Biotechnology industry, the median PB Ratio is 2.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Biotec's current PB Ratio is 3.03, which is 25% above median its own 10-year median of 2.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Biotec stock overvalued right now?
Based on GuruFocus' analysis, Panacea Biotec (BOM:531349) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹363.69, compared to a current price of ₹413.35 — trading 13.7% above its estimated fair value. The current PB Ratio is 3.03, which is 25% above median its 10-year median of 2.43 and 5.2% above the Biotechnology industry median of 2.88. Panacea Biotec's overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Panacea Biotec (BOM:531349), the current PB Ratio is 3.03 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panacea Biotec (BOM:531349) Overvalued in 2026?
Based on GuruFocus' analysis, Panacea Biotec stock appears to be overvalued.
The current stock price of ₹413.35 is trading 13.7% above its estimated GF Value™ of ₹363.69.
GuruFocus considers Panacea Biotec to be Modestly Overvalued.
Key valuation signals for BOM:531349:
PB Ratio: 3.03 (25% above median its 10-year median of 2.43)
GF Value™: ₹363.69 vs. price of ₹413.35 (13.7% above fair value)
Industry Position: 5.2% above the Biotechnology median (#617 of 1219)
No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
59GF Score
Get the complete analysis for BOM:531349
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531349 has been successfully added to your 
